A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
About This Bill
Committee
Latest Action · January 9, 2019
Read twice and referred to the Committee on the Judiciary.